Sentien Biotechnologies, Inc. awarded NIH Phase I SBIR Award for Liver Program

Filter:   PRESS RELEASES    IN THE NEWS    EVENTS

Sentien Biotechnologies, Inc. awarded NIH Phase I SBIR Award for Liver Program

Sentien was awarded a NIH Phase I SBIR grant to expand the companies’ platform cell therapy technology into a new therapeutic indication – acute liver injury.